Literature DB >> 22765899

Antileishmanial bis-arylimidamides: DB766 analogs modified in the linker region and bis-arylimidamide structure-activity relationships.

Carolyn S Reid1, Abdelbasset A Farahat, Xiaohua Zhu, Trupti Pandharkar, David W Boykin, Karl A Werbovetz.   

Abstract

Analogs of the lead antileishmanial bis-arylimidamide DB766 were prepared that possess unsymmetrical substitutions on the diphenylfuran linker, and an additional compound was synthesized that contains isopropoxy groups meta to the central furan. These agents all displayed nanomolar in vitro potency against intracellular Leishmania with selectivity indexes >100 compared to J774 macrophages. While the unsymmetrical analogs were toxic to mice when given ip at 30 mg/kg/day, the compound bearing the meta isopropoxy groups was well tolerated by mice and showed activity in a murine model of visceral leishmaniasis when administered ip at 30 mg/kg/day for five days.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22765899     DOI: 10.1016/j.bmcl.2012.06.037

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  7 in total

1.  Antileishmanial Efficacy and Pharmacokinetics of DB766-Azole Combinations.

Authors:  April C Joice; Sihyung Yang; Abdelbasset A Farahat; Heidi Meeds; Mei Feng; Junan Li; David W Boykin; Michael Zhuo Wang; Karl A Werbovetz
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

2.  Studies on the antileishmanial mechanism of action of the arylimidamide DB766: azole interactions and role of CYP5122A1.

Authors:  Trupti Pandharkar; Xiaohua Zhu; Radhika Mathur; Jinmai Jiang; Thomas D Schmittgen; Chandrima Shaha; Karl A Werbovetz
Journal:  Antimicrob Agents Chemother       Date:  2014-06-02       Impact factor: 5.191

3.  In vitro and in vivo studies of the biological activity of novel arylimidamides against Trypanosoma cruzi.

Authors:  J S De Araújo; C F Da Silva; D G J Batista; P B Da Silva; M B Meuser; C A F Aiub; M F V da Silva; C F Araújo-Lima; M Banerjee; A A Farahat; C E Stephens; A Kumar; D W Boykin; M N C Soeiro
Journal:  Antimicrob Agents Chemother       Date:  2014-03-03       Impact factor: 5.191

Review 4.  Novel amidines and analogues as promising agents against intracellular parasites: a systematic review.

Authors:  M N C Soeiro; K Werbovetz; D W Boykin; W D Wilson; M Z Wang; A Hemphill
Journal:  Parasitology       Date:  2013-04-08       Impact factor: 3.234

5.  Synthesis and Antileishmanial Evaluation of Arylimidamide-Azole Hybrids Containing a Phenoxyalkyl Linker.

Authors:  Ahmed Abdelhameed; Mei Feng; April C Joice; Emilia M Zywot; Yiru Jin; Chris La Rosa; Xiaoping Liao; Heidi L Meeds; Yena Kim; Junan Li; Craig A McElroy; Michael Zhuo Wang; Karl A Werbovetz
Journal:  ACS Infect Dis       Date:  2021-02-04       Impact factor: 5.578

6.  Engineered modular heterocyclic-diamidines for sequence-specific recognition of mixed AT/GC base pairs at the DNA minor groove.

Authors:  Pu Guo; Abdelbasset A Farahat; Ananya Paul; David W Boykin; W David Wilson
Journal:  Chem Sci       Date:  2021-11-02       Impact factor: 9.825

7.  Synthesis and pharmacological evaluation of mono-arylimidamides as antileishmanial agents.

Authors:  Xiaohua Zhu; Abdelbasset A Farahat; Meena Mattamana; April Joice; Trupti Pandharkar; Elizabeth Holt; Moloy Banerjee; Jamie L Gragg; Laixing Hu; Arvind Kumar; Sihyung Yang; Michael Zhuo Wang; David W Boykin; Karl A Werbovetz
Journal:  Bioorg Med Chem Lett       Date:  2016-03-25       Impact factor: 2.823

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.